Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 3/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539790 | 0.85 | PPARD (0.37) | PPARDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6539671 | 0.85 | PPARD (0.45) | PPARDSMN1; SMN2MAPTALDH1A1NR4A2 | |
| SCHEMBL6538787 | 0.85 | PPARD (0.41) | PPARDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6539770 | 0.84 | PPARD (0.38) | PPARDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6538838 | 0.84 | PPARD (0.38) | PPARDSMN1; SMN2 | |
| SCHEMBL6539465 | 0.83 | PPARD (0.41) | PPARDSMN1; SMN2NR4A2 | |
| SCHEMBL6539800 | 0.81 | PPARD (0.43) | PPARDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6538999 | 0.81 | PPARD (0.43) | PPARDALDH1A1KMT2AMEN1HTT | |
| SCHEMBL6539926 | 0.80 | PPARD (0.40) | PPARDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6539864 | 0.79 | PPARD (0.41) | PPARDALDH1A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885SMN1; SMN2 3341/4885MAPT 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.